General

Home>News>General

Cartherics hosts Frocktober afternoon tea for ovarian cancer awareness

Today, Cartherics proudly hosted a Frocktober Afternoon Tea in support of ovarian cancer awareness and research. Frocktober is a meaningful initiative that encourages us to go the extra style mile – turning heads, starting conversations, and raising vital funds for ovarian cancer research.

We were honoured to welcome Robin Penty, CEO of the Ovarian Cancer Research […]

2025-10-16T12:08:59+11:00October 15th, 2025|

The Next Generation of Cell Therapy with Cartherics’ COO Dr. Ian Nisbet

Cartherics’ COO, Dr Ian Nisbet recently joined Xtalks’ Life Science Podcast to discuss Cartherics vision for next generation cell therapies.  

He discussed how Cartherics’ platform is building an effectively unlimited supply of CAR NK cells and exploring treatments for underserved conditions like cancer and endometriosis. Dr Nisbet also reflects on his biotech leadership […]

2025-10-15T10:36:51+11:00October 1st, 2025|

Cartherics Wins ‘Most Promising iPSC Therapy Pipeline in APAC’ at Asia Pacific Cell & Gene Therapy Excellence Awards

Melbourne, Australia, 11 September 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is proud to announce that it has been named ‘Most Promising iPSC Therapy Pipeline in APAC’ in the Asia Pacific Cell […]

2025-09-12T12:21:47+10:00September 11th, 2025|

Cartherics CEO Prof. Alan Trounson featured on 10News+

Cartherics is proud to share that our CEO, Professor Alan Trounson, was recently interviewed on 10 News+ by journalists Amelia Brace and Denham Hitchcock.

In the interview, Prof. Trounson provided an in-depth look at Cartherics’ world-first immunotherapies and how this innovative science is shaping the future of treatment for some of the most difficult-to-treat diseases.

Our lead […]

2025-09-02T15:33:02+10:00September 2nd, 2025|

Cartherics Granted Chinese Patent for Enhancing Immune Cell Function

Melbourne, Australia, 27 August 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today announced the granting of a patent for ‘Method for Providing Immune Cells with Enhanced Function’ by the Chinese Patent Office.

This […]

2025-08-27T13:56:41+10:00August 27th, 2025|

Cartherics Unveils State-Of-The-Art Cleanroom Facility for Cell Therapy Manufacturing

Melbourne, Australia, 6 August 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune stem cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today unveiled its new, state-of-the-art cleanroom facility for clinical-scale manufacturing of cell therapy products.

The facility was officially opened by the […]

2025-08-06T16:32:36+10:00August 6th, 2025|

Congratulations Dr Mathew Tiedemann!

Cartherics is pleased to announce that Mathew Tiedemann has officially completed his PhD, a major milestone in an already impressive scientific journey! His thesis titled, ‘Developing a Clinically Translatable iPSC-derived Immunotherapy’ focused on designing clinically relevant methods to create billions of gene-edited blood cells from stem cells to better detect and destroy ovarian cancer.

Mat’s key […]

2025-07-16T11:23:57+10:00July 16th, 2025|

The critical importance of navigating the complexity of healthcare markets

In the competitive biotech landscape, groundbreaking science alone isn’t enough. As highlighted in a recent article by Dynamic Business, Cartherics’ strategic appointment of U.S. biotech executive Laurence Nore underscores the critical importance of navigating the complexity of healthcare markets. Laurence emphasises that many promising biotech firms falter not due to flawed science but because they […]

2025-07-11T11:46:36+10:00July 11th, 2025|

Cartherics COO Dr Ian Nisbet on the promise of CAR-NK cells for cancer and endometriosis at BIO 2025

In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative approach to cell therapy development. He discusses the transformative potential of CAR-NK cell therapies in treating solid tumours and endometriosis. These engineered natural killer cells, derived from iPSCs, are designed to target and eliminate cancer […]

2025-06-18T12:02:39+10:00June 18th, 2025|

Using Gene-edited Killer Cells to Target Cancer, Endometriosis and Beyond

Cartherics is delighted to be featured in the June 2025 issue of Pharma Technology Focus, drawing attention to our innovative approach to cell therapy. Unlike traditional cell therapies, Cartherics employs gene-edited natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) from umbilical cord blood.

This approach aims to enhance the immune system’s […]

2025-06-12T11:26:07+10:00June 12th, 2025|
Go to Top